Xinhua United Orthopaedics Completes Series A Funding Round and Files IPO Prospectus

Recently, Shandong Xinhua United Orthopedic Equipment Co., Ltd. ("Xinhua United"), an orthopedic medical device company, completed a multi-million yuan Series A round of financing. This round was exclusively invested by Shandong Health Fund under Huiyuan Capital. The proceeds will be used for the expansion of the R&D and manufacturing base for orthopedic medical devices, the development of supply chain and marketing across China, as well as strengthening product technology and academic advantages.

Shandong Xinhua United Orthopedic Equipment Co., Ltd. was established in 2016 as a joint venture between XinHua Medical (600587.SH) and Taiwan United (4129.TW). XinHua Medical, founded in 1943, is the first medical device manufacturing enterprise established by the Communist Party of China and the Chinese People's Liberation Army, and serves as the president unit of the China Association for Medical Devices Industry. Taiwan United, founded in 1993, is the first company in China engaged in the research, production, and sales of orthopedic implants, boasting a global sales network and extensive clinical experience.
Shandong Xinhua United Orthopedic Equipment Co., Ltd. focuses on high-value orthopedic consumables, with main products including hip joints, knee joints, spinal products, 3D-printed bone implant products, and specialized orthopedic tools, among others. The company owns independent intellectual property rights and has obtained 16 Class III medical device registration certificates in China. Its self-produced joint products have been listed in over 30 provinces and cities in China and have entered leading core hospitals. The company currently operates two major production bases in Zibo and Xi'an. The orthopedic industry is in a period of rapid transformation. The next 3-5 years will be a critical window for industry upgrading and the replacement of imported products with those produced in China. The company is currently at the inflection point of business growth. Through this round of financing, it will increase innovation and R&D investment in the field of high-value orthopedic consumables, continuously providing a series of efficient, durable, and economically accessible products as well as safe and reliable clinical solutions to benefit patients. Leveraging the strong shareholder resources of Xinhua Medical, United Orthopedics, and Huiyuan Capital, the company aims to rapidly achieve the commercialization of its full range of domestically produced products and consolidate its leading position in the industry.